Treatment strategies in essential thrombocythemia. A critical appraisal of various experiences in different centers

Leukemia and Lymphoma

Volumn 22, Issue SUPPL. 1, 1996, Pages 149-160

  Barbui, Tiziano ^a,d   Finazzi, Guido ^a   Dupuy, Evelyne ^b   Kiladjian, Jean Jacques ^c   Brière, Jean ^c  

^a Ospedali Riuniti Bergamo   (Italy)

^b HÔPITAL LARIBOISIÈRE   (France)

^c BEAUJON HOSPITAL   (France)

^d OSPEDALI RIUNITI   (Italy)

Author keywords

Essential thrombocythemia; Treatment strategy

Indexed keywords

ACETYLSALICYLIC ACID; ALKYLATING AGENT; ALPHA INTERFERON; ANAGRELIDE; BUSULFAN; CHLORAMBUCIL; HYDROXYUREA; IMMUNOSUPPRESSIVE AGENT; MELPHALAN; NITROSOUREA; PHOSPHORUS 32; PIPOBROMAN; RIBONUCLEOSIDE DIPHOSPHATE REDUCTASE; URAMUSTINE;

AGE; ALOPECIA; BLEEDING; BLOOD VESSEL OCCLUSION; BONE MARROW SUPPRESSION; BONE PAIN; CANCER RISK; CLINICAL TRIAL; CYTOPENIA; DIARRHEA; FATIGUE; HEADACHE; HEART PALPITATION; HIGH RISK POPULATION; HUMAN; HYPOTHYROIDISM; INFLUENZA; LEUKEMIA; LEUKOPENIA; MEGALOBLASTIC ANEMIA; MENTAL DISEASE; MYALGIA; NAUSEA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK BENEFIT ANALYSIS; TACHYCARDIA; THROMBOCYTE COUNT; THROMBOCYTHEMIA; THROMBOSIS; VERTIGO;

EID: 0029858928     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.3109/10428199609074373     Document Type: Review

References (86)

1. Murphy, S. (1983) Thrombocytosis and thrombocythemia. Clin. Haematol., 12, 89-105.
2. Van Genderen, P. J. J., Michiels, J. J. (1994) Erythromelalgic, thrombotic and hemorrhagic manifestations in thrombocythemia. Presse Médicale, 23, 73-77.
3. Murphy, S., Rosenthal, D. S., Weinfeld, A., Briere, J., Faguet, G. B., Knospe, W. H., Landaw, S. A., Laszlo, J., Pisciotta, A. V., Tartaglia, A. P., Golberg, J. D., Berk, P. D., Donovan, P. B. and Wasserman, L. R. (1982) Essential thrombocythemia: response during first year of therapy with Melphalan and radioactive phosphorus: a Polycythemia Vera Study Group report. Cancer Treat. Rep., 66, 1495-1500.
4. Barbui, T., Cortelazzo, S., Viero, P., Bassan, R., Dini, E., Semeraro, N. (1983) Thrombohaemorrhagic complications in 101 cases of myeloproliferative disorders : relationship to platelet number and function. Eur. J. Cancer Clin. Oncol., 19, 1593-1599.
5. Buss, D. H., Stuart, J. J. and Lipscomb, G. E. (1985) The incidence of thrombotic and hemorrhagic disorders in association with extreme thrombocytosis : an analyse of 129 cases. Am. J. Hematol., 20, 365-372.
6. Bellucci, S., Janvier, M., Tobelem, G., Flandrin, G., Charpak, Berger, R., Boiron M. (1986) Essential thrombocythemias. Clinical evolutionary and biological data. Cancer, 58, 2440-2447.
7. Van de Pette, J. E. W., Prochazka, A. V., Pearson, T. C., Singh, A. K., Dickson, E. R. and Wetherley-Mein, G. (1986) Primary thrombocythaemia treated with busulfan. Brit. J. Haematol., 62, 229-237.
8. Murphy, S., Hand, H., Rozenthal, D., Lazlo, J. (1986) E. T.: an interim report from the P.V.S.G. Semin. Hematol., 23, 177-182.
9. Hehlmann, R., Jahn, M., Baumann, B. and Kopeke, W. (1988) Essential thrombocythemia. Clinical characteristics and course of 61 cases. Cancer, 61, 2487-2496.
10. Grossi, A., Rosseti, S., Vannucchi, A. M., Rafanelli, D., Ferrini, P. R. (1988) Occurence of haemorrhagic and thrombotic events in myeloproliferative disorders. Clin. Lab. Haemal., 10, 167-175.
11. Lahuerta-Palacios, J.J., Bornstein, R., Fernandez-Debora, F. J., Gutierrez-Rivas, E., Ortiz, M. C., Larregla, S., Calandre, L. and Montero-Castillo, J. (1988) Controlled and uncontrolled thrombocytosis. Its clinical role in essential thrombocythemia. Cancer, 61, 1207-1212.
12. Randi, M. L., Fabris, F., Rossi, C., Tison, T., Barbone, E., Girolam, A. (1992) Sex and age as prognostic factors in essential thrombocythemia. Haematologica, 77, 402-404.
13. Cortelazzo, S., Viero, P., Finazzi, G., D'Emilio, A, Rodeghiero, F. and Barbui, T. (1990) Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia. J. Clin. Oncol., 8, 556-562.
14. Fenaux, P., Simon, M., Caulier, M. T., Lai, J. L., Goudemand, J. and Bauters, F. (1990) Clinical course of essential thrombocythemia in 147 cases. Cancer, 66, 549-556.
15. Millard, F. E., Hunter, C. S., Anderson, M., Edelman, M. J., Kosty, M. P., Luiken, G. A. and Marino, G. G. (1990) Clinical manifestations of essential thrombocythemia in young adults. Am. J. Hematol., 33, 27-31.
16. Mc Intire, K. J., Hoagland, H. C., Silverstein, M. N. and Petit, T. (1991) Essential thrombocythemia in young adults. Mayo Clin. Proc., 66, 149-154.
17. Colombi, M., Radaelli, F., Zocchi, L., Maiolo, A. T. (1991) Thrombotic and hemorrhagic complications in essential thrombocythemia. A retrospective study of 103 patients. Cancer, 67, 2926-2930.
18. Watson, K. V. and Key, N. (1993) Vascular complications of essential thrombocythaemia: a link to cardiovascular risk factors. Brit. J. Haematol., 83, 198-203.
19. Dupuy, E. (1994) Personal communication.
20. Turlure, P., Le Prise, P.Y., Letortorec, S., Linassier, C., Ifrah, N., Desablens, B., Tourani, J. M., Lejeune, F., Sensebe, L., Briere, J. B. (1993) Essential thrombocythemia (E.T.) clinical course and results of a multicenter prospective study. Blood, 82, supl 1 197 (abst 775).
21. Mitus, A. J., Barbui, T., Shulman, L. N., Rosenthal, D. S., Viero, P., Cortelazzo, S., Schafer, A. I. (1990) Hemostatic complications in young patients with essential thrombocythemia. Am. J. Med., 88, 371-375.
22. Schafer, A. I. (1984) Bleeding and thrombosis in myeloproliferative disorders. Blood, 64, 1-12.
23. Budde, U., Schaefer, G., Mueller, N., Egli, H., Dent, J., Ruggeri, Z. M., Zimmerman, T. S. (1984) Acquired von Willebrand's disease in the myeloproliferative syndrome. Blood, 64, 981-985.
24. Budde, U., Scharf, R. E., Franke, P., Hartman-Budde, K., Dent, J., Ruggeri, Z. M. (1993) Elevated platelet count as a cause of abnormal von Willebrand factor multimer distribution in plasma. Blood, 82, 1749-1757.
25. Van Genderen, P. J. J., Michiels, J. J., van der Poel-van de Luytgaarde SCPAM., van Vliet HHDM (1994) Acquired von Willebrand disease as a cause of recurrent mucocutaneous bleeding in primary thrombocythemia: relationship with platelet count. Ann. Hematol., 69, 81-84.
26. Goodman, E., Gilmans's (1985) Hydroxyurea. In The Pharmacological Basis of Therapeutics, edited by Mac Millan Publishing Company, p: 1291-1292, New York.
27. Van Genderen, P. J. J., Michiels, J. J. (1993) Primary thrembocytemia: diagnosis, clinical manifestations and management. Ann. Hematol., 67, 57-62.
28. Tobelem, G. (1989) Essential thrombocythaemia. Baillières Clin. Hematology, 2, 719-728.
29. Lofvenberg, E., Walhlin, A. (1988) Management of polycythaemia vera, essential thrombocythaemia and myelofibrosis with Hydroxyurea. Eur. J. Haematol., 41, 375-381.
30. Pearson, T. C.(1991) Clinical annotation. Primary thrombocythaemia : diagnosis and management. Brit. J. Haematol., 78, 145-148.
31. Cortelazzo, S., Finazzi, G., Ruggeri, M., Vestri, O., Galli, M., Rodeghiero, F., Barbui, T. (1995) Hydroxyurea in the treatment of patients with essential thrombocythemia at high risk of thrombosis: a prospective randomized trial. N. Engl. J. Med., 332, 1132-1136.
32. Michiels, J. J., Koudstall, P. J., Muller, A. H., van Vliet, H. H. D. M. (1993) Transient neurological and occular manifestations in primary thrombocythemia. Neurology, 43, 1107-1110.
33. Scheffer, M. G., Michiels, J. J., Simoons, M. L., Roetlandt (1991) Thrombocythemia and coronary artery disease. Am. Heart J., 22, 573-576.
34. Roznan, C., Giralt, M., Feliu, E. et al. (1991) Life expectancy of patients with chronic non leukemic myeloproliferative disorders. Cancer, 67, 2658-2663.
35. Balduini, C. L., Bertolino, G., Noris, P., Piletta, G. C. (1991) Platelet aggregation in platelet-rich plasma and whole blood in 120 patients with myeloproliferative disorders. Am. J. Clin. Pathol., 95, 82-86.
36. Murphy, S., Peterson, P., Iland, H. J., Fruchtman, S. (1993) Hydroxyurea and other myelosuppressive agents in the treatment of essential thrombocythemia : analysis of leukemogenic potential. Thromb. Haemostas., 69, (suppl) 554 (abst.).
37. Shibata, K. Shimamoto, Y., Suga, K., Sano, M., Matzuzaki, M., Ymaguchi, M. (1994) Essential thrombocythemia terminating in acute leukemia with minimal myeloid differentiation. A brief review of recent literature. Acta. Haematol., 91, 84-88.
38. Lofvenberg, E., Nordenson, I., Walhlin, A. (1990) Cytogenetic abnormalities and leukemic transformation in hydroxyurea-treated patients with Philadelphia chromosome negative chronic myeloproliferative disease. Cancer Genet. Cytogenet., 49, 57-67.
39. Kutti, J. (1990) The management of thrombocytotosis. Eur. J. Haematol, 44, 81-88.
40. Brandt, L., Anderson, H. (1995) Survival and risk of leukaemia in polycythaemia vera and essential thrombocythaemia treated with oral radiophosphorus: are safer drugs available? Eur. J. Haematol., 54, 21-26.
41. Stott, H., Wallace, F., Girling, D. J., Stephens, R. J., Galton D. A. G. (1977) Acute leukaemia after busulfan. B.M.J., 2, 1513-1517.
42. Weinfeld, A., Swolin, B., Westin, J. (1994) Acute leukaemia after hydroxyurea therapy in polycythaemia vera and allied disorders: prospective study of efficacy and leukaemogenicity with therapeutic implications. Eur. J. Haematol., 52, 134-139.
43. West, W. O. (1987) Hydroxyurea in the treatment of polycythaemia vera. South Med. J., 80, 323-327.
44. Kaplan, M. E., Mack, K., Goldberg, J. D., Donavan, P. B., Berk, P. D. (1986) Long term management of polycythaemia vera with hydroxyurea: a progress report. Semin. Hematol., 23, 167-171.
45. Nand, S., Messmore, H., Fisher, S. G., Bird, M. L., Schulz, W., Fisher, R. I. (1990) Leukemic transformation in polycythemia vera: analysis of risk. Am. J. Hematol., 34, 32-36.
46. Landavv, S. A. (1995) Acute leukemia in polycythaemia vera. Edited by Wasserman, L. R., Berk, P. D., Berlin, N. I., p. 154-165. USA: WB Saunders Company.
47. P. Boivin (1991) Indications, procedure and results for the treatment of Polycythaemia vera by bleeding, pipobroman and hydroxyurea. Nouv. Rev. Ft. Hematol., 35, 491-498.
48. Bond, W. H. (1962) Evaluation of compound 8103-Abott (N, N′-bis (3 biomopropionyl) Piperazine in patients with polycythemia vera. Proc. Am. ASDC. Cancer Res., 3, 306.
49. Bauters, F., Jouet, J. F., Goudemand, M. (1976) Un traitement méconnu des polyglobulies primitives: le Pipobroman. A propos de 13 observations. Lille Médical: 202-208.
50. Bernard, J. F., Renoux, M., Dhermy, D., Lallemand, R., Boivin, P. (1978) Traitement de la polyglobulie primitive de Vaquez par le Pipobroman. Résultats obtenus chez 63 malades traités entre 1969 et 1977. Nouv: Press. Med., 7, 3527-3530.
51. Bilski-Pasquier, G., Blanc, C. M., Bousser, J. (1968) Traitement de la polycythémie de Vaquez par le 1-4-his (3 bromopropionyl Piperazine). Press. Med., 76, 1953-1956.
52. Najean, Y., Dresch, C., Rain, J. D. (1991) Intermediate analysis of e French protocol on Polycythaemia Vera: 253 patients. Nouv. Rev. Fr. Hematol., 33, 201-203.
53. Najman, A., Stachowiak, J., Parlier, Y., Gorin, N. C., Duhamel, G. (1982) Pipobroman therapy of Polycythaemia Vera. Blood, 59, 890-894.
54. Brusamolino, E., Canavari, A., Salvaneschi, L., Merante, S. and Bernasconi, C. (1984) Efficacy trial of Pipobroman in essential thrombocythemia: a study of 24 patients. Cancer Treat. Reports, 68, 13391342.
55. Mazzucconi, M. G., Francesconi, M., Chistolini, A., Falcione, E., Ferrari, A., Tirindelli, M. C. and Mandelli, F. (1986) Pipobroman therapy of essential thrombocythemia. Scand. J. Haematol., 37, 306-309.
56. Bauters, F. Personnal communication.
57. Gisslinger, H., Chott, A., Scheithauer, W., Gilly, B., Linkesch, W., Ludwig, H. (1991) Interferon in essential thrombocythamia. Brit. J. Haematol., 79 (suppl. 1), 42-17.
58. Giles, F. J. (1991) Maintenance therapy in the myeloproliferative disorders: the current options. Brit. J. Haematol., 79 (suppl. 1), 92-95.
59. Lazzarino, M., Vitale, A., Morra, E., Gagliardi, A., Bernasconi, P., Torromeo, C., Inverardi, D., Burgio, B., Castello, A., Bernasconi, C. and Mandelli, F. (1989) Interferon alpha 2b as treatment for Philadelpha-negative chronic myeloproliferative disorders with excessive thrombocytosis. Brit. J. Haematol., 72 173-177.
60. Turn, D., Mitra, M. E., Di Trapani, R., Lipari, M. G., Perricone, R., Cajozzo, A. (1991) Alpha-interferon in polycythemia vera and essential thrombocythemia. Haematologica, 76, 75-77.
61. Yataganas, X., Meletis, J., Plata, E., Viniou, N., Deligiannis, F., Tsekoura, C., Voscaridou, E., Boussiotis, V., Rombos, J., Vayopoulos, G., Kittas, C. and Fessas, P. (1991) Alpha interferon treatment of essential thrombocythaemia and other myeloproliferative disorders with excessive thrombocytosis. Eur. J. Cancer, 27, 569-571.
62. Giralt, M., Rubio, D., Cortes, M. T., San Miguel, J., Steegmann, J. L., Serena, J. Fernandez-Ranada, J. and Lopez-Borrasca, A. (1991) Alpha interferon in the management of essential thrombocythaemia. Eur. J. Cancer, 27, 572-574.
63. Rametta, V., Ferrara, F., Marottoli, V., Matera, C., Mettivier, V., Cimino, R. (1994) Recombinant interferon alpha 2b as treatment of essential thrombocythaemia. Acta Haematol., 91, 126-129.
64. Middelhoff, G. and Boll, I. (1992) A long-term clinical trial of interferon alpha-therapy in essential thrombocythemia. Ann. Hematol., 64, 207-209.
65. Sacchi, S., Tabilio, A., Leoni, P., Riccardi, A., Vecchi, A., Messora, C., Falzetti, F., Rupoli, S., Ucci, G., Martelli, M. F. (1991) Interferon alpha-2b in the long term treatment of essential thrombocythemia. Ann. Hematol., 63, 206-209.
66. Han, Z. C., Briere, J., Abgrall, J. F., Legau, G., Parent, D., Sensebe, L. (1987) Effects of recombinant human interferon alpha on human megacaryocyte and fibroblast colony formation. Journal of biological regulators and homeostatic agents, 1, 195-200.
67. Gugliotta, L., Bagnara, G. P., Catani, L., Gaggioli, L., Guarini, A., Zauli, G., Belmonte, M. M., Lauria, F., Macchi, S. and Tura, S. (1989). In vivo and in vitro inhibitory effect of alpha-interferon on megakaryocyte colony growth in essential thrombocythaemia. Brit. J. Haematol., 71, 177-181.
68. Bellucci, S., Harousseau, J. L., Brice, P., Tobelem, G. (1988) Treatment of essential thrombocythaemia by alpha 2a interferon. Lancet, 22 Oct. 960-961..
69. Kasparu, H., Bernhart, M., Krieger, O., Lutz, D. (1992) Remission may continue after termination of rIFNα-2b treatment for essential thrombocythemia. Eur. J. Haematol., 48, 33-36.
70. Petit, J. J., Callis, M., Fernandez, De Sevilla, A. (1992) Normal pregnancy in a patient with essential thrombocythemia treated with interferon alpha 2b. Am. J. Hematol., 40, 80.
71. Silverstein, M. N., Petitt, R. M., Solberg, L. A., Fleming, J. S., Knoght, R. C., Schacter, L. P. (1988). Anagrelide: a new drug for treating thrombocytosis. N. Engl. J. Med., 318, 1292-1294.
72. Solberg, L. A., Oles, K. J., Tarach, J., Silverstein, M. N., Petitt, R. M. et al. (1989). The effects of Anagrelid on human megakaryocytopoiesis. Blood, 74 (suppl. 1), 10 (Abst. 62).
73. Andes, W. A., Noveck, R. J., Fleming, J. S. Inhibition of platelet production induced by an antiplatelet drug, anagrelide, in normal volunteers. Thromb. Haemos., 1984, 52, 325-328.
74. Mazur, E. M., Rosmarin, A. G., Sohl, P. A., Newton, J. L., Naradran, A. (1992). Analysis of the mechanism of anagrelideinduced thrombocytopenia in humans. Blood, 79, 1931-1937.
75. Mazzucconi, M. G., De Sanctis, V., Christolini, A., Dragoni, F., Mandelli, F. (1992) Therapy with anagrelide in patients affected by essential thrombocythemia: preliminary results. Hematologica, 77, 315-317.
76. Silverstein, M. N., Petitt, R. M., Solberfg, L. A., Rosenbloom, B., Silver, R. T. et al (1992) Anagrelide, a therapy for thrombocythemic states. Experience in 577 patients. Amer. J. Med., 92, 69-76.
77. Silver, R. T., Zaattrowski, T. P., Caruso, F., Chapman, C., Schacter, I. P. et al (1992) Thrombocytosis refractory to hydroxyurea in chronic myeloid leukemia (CML) responds to anagrelide. Brit. J. Haemat., 80, 177 (abs. 530).
78. Balduini, C. L., Bertolino, G., Noris, P., Ascari, E. (1992) Effect of anagrelide on platelet count and function in patients with thrombocytosis and myeloproliferativce disorders. Haematologica, 7, 740-743.
79. Mc Intyre, K. J., Hoagland, H. C., Silverstein, M. N., Petitt, R. M. (1991) Essential thrombocythemia in young adults. Mayo Clin. Proc., 66, 149-154.
80. Chintagumpala, M. M., Steuber, C. P., Mahoney, Jr. D. H., Ogden, A. K., Fernbarch, D. J. (1991) Essential thrombocythemia in a child: management with anagrelide. Am. J. Ped. Hematol. Oncol., 13, 52-56.
81. Murphy, S., Rosenthal, D. S., Weinfeld, A., Briere, J., Faguet, G. B., Knospe, W. H., Landaw, S. A., Laszlo, J., Pisciotta, A. V., Tartaglia, A. P., Golberg, J. D., Berk, P. D., Donovan, P. B. and Wasserman, L. R. (1982) Essential thrombocythemia: response during first year of therapy with Melphalan and radioactive phosphorus: a Polycythemia Vera Study Group report. Cancer Treat. Rep., 66, 1495-1500.
82. De Pauw, B. E., Van, Bergen, A. N., Haanen, C., Steenbergen, J. (1985) Intermittent melphalan in the treatment of essential thrombocytosis with haemorrhage or thrombosis. Scand. J. Haematol., 35, 448-450.
83. Case, D. C. Jr. (1984). Therapy of essential thrombocythemia with thiotepa and chlorambucil. Blood, 63, 51-54.
84. Shamasunder, H. K.; Gregory, S. A., Knospe, W. H. (1980) Uracil mustard in the treatment of thrombocytosis. Jama, 244, 1454-1455.
85. Kanoh, T. (1990) Ranimustine: a new drug for treating essential thrombocythemia. Blood, 76 (suppl. 1), 287 (abst. 1140).
86. Brosdky, I. (1982) Busulfan treatment of polycythaemia vera (Annotation). Brit. J. Haematol., 52, 1-6.